Neogen Corporation (NEOG) Stock Price & How to Invest

Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and support animal health. It operates in two segments: Food Safety (roughly 70% of sales after the 3M Food Safety acquisition), which tests for pathogens, spoilage organisms, toxins, and allergens, and Animal Safety, which sells veterinary instruments, diagnostics, disinfectants, rodent and insect control products, and life science reagents. The Food Safety segment is now the larger contributor and the strategic core following the transformative 3M deal.

The investment picture is dominated by that 3M integration. Neogen took on significant leverage and has posted GAAP net losses in recent quarters, largely from acquisition-related amortization, even as adjusted EBITDA stays positive. Management is streamlining the portfolio, agreeing in 2026 to sell its global genomics business (GeneSeek) to Zoetis for ~$160 million with proceeds earmarked for debt reduction. The bull case rests on stable, recurring testing demand and deleveraging; the bear case centers on execution risk, share loss to larger rivals, and the time needed to reach durable profitability.

Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.

3 analysts publish price targets on NEOG, averaging $13.33 against a $11.64 price as of September 2026, or +14.5%. The published targets run from $12.00 to $14.00, a narrow spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NEOG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Neogen Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Recurring food safety testing demand. Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. The most optimistic published target, $14.00, assumes this works close to its best case.

The case against. Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The most pessimistic target, $12.00, is roughly what NEOG is worth if this bites instead.

Read the full bull and bear case on NEOG, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Neogen Corporation (NEOG) has had 2 share splits in the last 10 years:

• 1333:1000 on January 2, 2018, so every share held became 1.333 shares.
• 2:1 on June 7, 2021, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of NEOG the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Neogen Corporation's investor relations page or your broker.

• Revenue (FY2026 guidance): ~$857-860M
• Adjusted EBITDA (FY2026): ~$175M
• Q3 FY2026 revenue: ~$211M
• Q3 FY2026 net loss: ~-$17M
• Market cap: ~$2.1B
• Share price: ~$9-10

Neogen posts positive adjusted EBITDA (~$175M target) but recent GAAP results show net losses, largely from 3M acquisition amortization. The gap between adjusted and reported figures, plus elevated debt, is why valuation is contested despite a multi-billion-dollar market cap on roughly $855M of sales.

Other names that sit close to NEOG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NEOG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NEOG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NEOG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

NEOG is a turnaround-and-integration story where the investment case hinges on whether Neogen can convert its expanded scale into profitable, cash-generating growth while paying down debt.

Whether NEOG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NEOG a buy or a sell?, and where the stock could go from here in the NEOG stock forecast.

For income investors, whether NEOG pays a dividend and how the payout looks is covered in does NEOG pay a dividend? And to weigh NEOG against a peer, read the full side-by-side comparisons: NEOG vs TMO and NEOG vs QGEN.